Goldline Pharmaceutical Limited SME IPO: High GMP or Risky Bet? Full Details

By /
Goldline Pharmaceutical Limited SME IPO
GP
Goldline Pharmaceutical Limited IPO
Pharmaceutical Marketing · Asset-light Model · Goldline Brand · 130+ SKU Range
📋 SME IPO Fresh Issue BSE SME
₹43
Upper Price
₹11.61 Cr
Issue Size
May 19, 2026
Listing Date
₹41.28 Cr
Market Cap
📅 IPO Timetable
All dates tentative
🟢
IPO Opens
Tuesday, 12 May 2026
Bidding starts — apply before close
🔒
IPO Closes
Thursday, 14 May 2026
Last day to bid — closes at 5:00 PM IST
📊
Friday, 15 May 2026
Allotment finalised by registrar
🔄
Refund & Share Credit
Monday, 18 May 2026
Unallotted funds returned; shares credited to demat
🏷️
Tuesday, 19 May 2026
Trading begins from 10:00 AM IST
📋 IPO Details
IPO Open Date12 May 2026 (Tue)
IPO Close Date14 May 2026 (Thu)
Listing Date19 May 2026 (Tue)
Face Value₹10 per share
Price Band₹41 to ₹43
Issue Price (Upper Band)₹43 per share
Issue TypeBook Build — Fresh Issue
Lot Size3,000 shares
Total Issue Size27,00,000 shares (₹11.61 Cr)
Fresh Issue27,00,000 shares (₹11.61 Cr)
Offer for Sale (OFS)N/A
Market Maker Shares1,38,000 shares
Pre-Issue Shares69,00,000
Post-Issue Shares96,00,000
Promoter Holding (Pre)79.70%
Listing ExchangeBSE SME
Lead ManagerCumulative Capital
RegistrarBigshare Services
💰 Lot Size & Minimum Investment
At upper price ₹43
Investor TypeLotsSharesAmount
Retail — Minimum & Maximum26,000₹2,58,000
S-HNI (sNII) — Min39,000₹3,87,000
S-HNI (sNII) — Max721,000₹9,03,000
B-HNI (bNII) — Min824,000₹10,32,000
⚠️ SME IPO Note: Minimum application for retail is 2 lots (6,000 shares = ₹2,58,000). Retail maximum limit is also 2 lots. Lot size is 3,000 shares; bids must be in multiples thereof.
👥 Investor Reservation
Total 27,00,000 shares
49.65%
QIB Portion
12,72,000 shares
35.13%
Retail (RII)
9,00,000 shares
15.22%
NII / HNI
3,90,000 shares
💡 Market Maker: Nirman Share Brokers Pvt.Ltd. has been allocated 1,38,000 shares (5.11% of issue) to ensure liquidity post-listing on BSE SME.
📊 Live Subscription Status
Day 1 Details
Qualified Institutional (QIB)1.31x
Non-Institutional (NII)23.32x
Retail Individual (RII)32.37x
Total Subscription21.28x
📈 Company Financials
Restated · ₹ Crore
Metric31 Dec 202531 Mar 202531 Mar 202431 Mar 2023
Total Assets27.4026.2822.9319.39
Total Income21.4128.0623.5719.85
PAT2.222.831.810.26
EBITDA4.165.834.302.19
Net Worth12.3610.357.865.89
Total Borrowing9.4711.0311.1310.83
Income Growth
FY 2023–24₹23.57 Cr
FY 2024–25₹28.06 Cr
9M FY26 (Dec 2025)₹21.41 Cr
🎯 Key Performance Indicators
35.83%
ROE
FY 2024–25
38.45%
ROCE
FY 2024–25
10.09%
PAT Margin
FY 2024–25
1.50
Debt/Equity
FY 2024–25
21.02%
ROE (9M FY26)
Dec 31, 2025
24.22%
ROCE (9M FY26)
Dec 31, 2025
10.38%
PAT Margin
Dec 31, 2025
3.47x
Price/Book
Dec 31, 2025
⚖️ Valuation & EPS
Pre-IPO EPS
₹4.11
FY25 earnings / pre-issue shares
P/E: 10.47x
Post-IPO EPS
₹3.09
Annualised 9M FY26 / post-issue shares
P/E: 13.93x
Price to Book Value
3.47x
At upper price band (Dec 2025 book)
Market Cap (Pre-IPO)
₹41.28 Cr
At issue price ₹43
ℹ️ Pre-IPO EPS (₹4.11) based on pre-issue shareholding (69,00,000) and FY25 earnings. Post-IPO EPS (₹3.09) based on post-issue shareholding (96,00,000) and annualised 9M FY26 earnings.
🎯 Objects of the Issue
Net proceeds utilisation
1
Prepayment or repayment of all or a portion of certain outstanding borrowings availed by Company
₹8.35 Cr
2
General corporate purposes
Balance
Total Net Proceeds Target ₹8.35 Cr
🏢 About Goldline Pharmaceutical Limited
Est. 2022 · Nagpur, Maharashtra · Pharma Marketing

Goldline Pharmaceutical Limited is an asset-light pharmaceutical marketing company that operates under the flagship “Goldline” brand. The company specializes in identifying market needs and partnering with 15 manufacturing partners to produce tailored therapeutic solutions across several Indian states.

The company’s range includes over 130 products divided into specialized segments such as Goldline Pharma, Cardinal, Aayushman, InLife, and Wellness. Serving specialties from Cardiology to Critical Care, the company leverages a established network of 7 distributors to supply hospitals, wholesalers, and retailers in regions including Maharashtra, Tamil Nadu, and Rajasthan.

Core Divisions
💊
Goldline Pharma
42 products for specialties like ENT, Neurology, and Urology
❤️
Cardinal & Aayushman
Tailored solutions for Cardiology, Diabetology, and Pediatric care
🚨
InLife Critical Care
22 products serving intensivists and super specialty surgeons
🎯
Wellness & Support
Supportive care products for cancer therapy and recovery
Competitive Strengths
✅Asset-light business model with diversified and scalable therapeutic portfolios
🌐Established distribution network across 7 states with strong hospital relationships
🤝Strategic partnerships with 15 quality-certified third-party manufacturing units
👨‍💼Management team with significant domain knowledge and operational track record
Company Promoters
AM
Amol Laxmikant Mujumdar
Promoter, Goldline Pharmaceutical Limited
SK
Swapan Premprakash Khandelwal
Promoter, Goldline Pharmaceutical Limited
📅 Key Dates
IPO Opens12 May 2026
IPO Closes14 May 2026
Allotment15 May 2026
Refund & Share Credit18 May 2026
Listing Day19 May 2026
💡 Quick Summary
Price Band₹41 – ₹43
Issue Price₹43 / share
Lot Size3,000 shares
Min. Investment (Retail)₹2,58,000 (2 lots)
Issue Size₹11.61 Cr
ListingBSE SME
🏦 Registrar & Lead Manager
Registrar
Bigshare Services Pvt.Ltd.
📞 +91-22-6263 8200
[email protected]
Lead Manager
Cumulative Capital Pvt.Ltd.
Market Maker
Nirman Share Brokers Pvt.Ltd.
📍 Registered Address
Goldline Pharmaceutical Ltd.
103, F-1, Leela Apartment, Shilpa HSG Society,
Shanidham, Narendra Nagar, Nagpur,
Maharashtra — 440015
📞 +91 712 2786666
[email protected]
🛡️ Regulatory Note: SME IPO investments are subject to SEBI regulations. Always read the Prospectus/RHP before applying. Consult a SEBI-registered advisor before investing.
⚠️ Disclaimer: This page presents publicly available information from the Goldline Pharmaceutical IPO RHP for informational purposes only. It does not constitute investment advice. IPO investments are subject to market risk. Please read all offer documents and consult a SEBI-registered advisor before investing.
📊
Track Goldline Pharmaceutical Limited SME IPO: High GMP or Risky Bet? Full Details GMP
Check real-time grey market premium, daily GMP history & estimated listing price.
Check GMP →

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top